Neovasc has been selected as a finalist in this year’s Fierce Innovation Awards – LifeSciences Edition, for the Reducer product. The Fierce Innovation Awards is a peer reviewed awards program from the publisher of FierceBiotech and FiercePharma and highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharma companies.
Finalists’ applications were reviewed by an exclusive panel of executives from major biotech and pharma companies and were evaluated based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation.
Note: The CCS class is a functional classification used to stratify the severity of angina by evaluating angina symptoms with activity levels. N Eng J Med 2015;372:519-527
The Reducer has been added to the European Society of Cardiology Practice Guidelines at the highest recommendation class for therapies addressing refractory angina. learn more >
Positive results from the COSIRA clinical trial. here >
A library of publications about the ReducerTM here >
This device is currently only available
in the EU, Israel and Saudi Arabia.